V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 220009279 | 220012033 | 1.71 | 90.1 | Curative (C) | 2015-06-01 | 2015-06-01 | CISPLATIN + DOCETAXEL + FLUOROURACIL | 02 | N | 220036294 | FLUOROURACIL |
| 220009280 | 220012033 | null | 70.7 | Curative (C) | 2014-12-29 | 2015-01-01 | ALEMTUZUMAB + BUSULFAN + FLUDARABINE | 02 | N | 220036294 | FCR |
| 220009281 | 220012033 | 1.75 | 80 | null | 2012-07-17 | 2012-07-17 | CETUXIMAB + IRINOTECAN + MDG | N | N | 220036294 | RUXOLITINIB |
| 220009282 | 220012033 | null | null | Palliative (P) | 2014-08-20 | 2014-09-10 | FLUOROURACIL + MITOMYCIN + RT | N | N | 220036294 | CISPLATIN + ETOPOSIDE |
| 220009283 | 220003768 | 1.78 | 58 | Not known (9) | 2015-12-08 | 2015-12-11 | LANREOTIDE | 02 | N | 220036303 | CAPECITABINE + CISPLATIN + EPIRUBICIN |
| 220009284 | 220012034 | 1.71 | 70.95 | Curative (C) | null | 2016-02-03 | RUXOLITINIB | Y | N | 220036306 | UKALL2014 |
| 220009285 | 220012034 | 1.59 | 111 | Curative (C) | 2017-09-07 | 2017-09-09 | Cetuximab + FOLFIRI cycle 2 onwards | N | N | 220036306 | SPIRIT TRIAL |
| 220009286 | 220012034 | null | null | Curative (C) | 2017-02-02 | 2017-02-02 | Methotrexate High Dose (3g/m2) | 02 | Y | 220036306 | CYCLOPHOSPHAMIDE |
| 220009287 | 220020527 | null | null | null | 2017-12-02 | 2017-12-02 | Cisplatin + Fluorouracil + RT 5day | N | N | 220036313 | VEMURAFENIB |
| 220009288 | 220020527 | null | null | Curative (C) | null | 2017-10-24 | Arsenic trioxide + Tretinoin | null | null | 220036313 | CYTARABINE + MITOXANTRONE |
| 220009289 | 220020527 | 1.76 | 12.4 | Adjuvant (A) | 2015-12-28 | 2015-12-29 | IDARUBICIN + MITOXANTRONE + Tretinoin | 02 | N | 220036313 | CISPLATIN + FLUOROURACIL |
| 220009291 | 220012035 | 1.62 | 69 | Adjuvant (A) | 2013-12-02 | 2016-08-12 | ALEMTUZUMAB + BUSULFAN + FLUDARABINE | N | N | 220036329 | CARBOPLATIN + RT |
| 220009293 | 220003771 | 1.49 | 60.7 | Disease modification (D) | 2014-04-12 | 2014-04-12 | Capecitabine (14 days)+Carboplatin | N | N | 220036331 | BOSUTINIB |
| 220009294 | 220003772 | 1.65 | 120 | Curative (C) | 2017-08-03 | 2017-09-07 | CAPECITABINE + EPIRUBICIN + OXALIPLATIN | N | N | 220036332 | DAUNORUBICIN |
| 220009295 | 220012036 | 1.62 | 81.5 | Disease modification (D) | 2017-03-11 | 2017-03-11 | CAPECITABINE + CARBOPLATIN + EPIRUBICIN | N | N | 220036334 | CABOZANTINIB |
| 220009296 | 220012036 | 1.58 | 56.8 | Palliative (P) | 2015-03-13 | 2015-03-13 | Triple Intrathecal | N | N | 220036334 | OCTREOTIDE |
| 220009297 | 220012036 | 1.75 | 53.6 | Curative (C) | 2012-03-14 | 2015-04-13 | Capecitabine | N | N | 220036334 | CISPLATIN |
| 220009298 | 220003773 | null | null | Curative (C) | 2016-01-06 | 2016-01-06 | Fludarabine + Melphalan RIC Allo | N | N | 220036338 | CODOX M |
| 220009299 | 220003773 | 1.65 | 104 | Curative (C) | 2016-06-05 | 2016-06-24 | Doxorubicin + Ifosfamide | 02 | null | 220036338 | BOSUTINIB |
| 220009300 | 220003774 | 1.71 | 97.7 | Curative (C) | 2013-03-16 | 2013-03-16 | Fludarabine + Melphalan RIC Allo | N | N | 220036347 | CYTARABINE + ETOPOSIDE + IDARUBICIN |
| 220009305 | 220016506 | 1.7 | 12.4 | Curative (C) | 2016-06-25 | 2016-06-25 | Busulfan Oral | N | N | 220036358 | ARSENIC TRIOXIDE |
| 220009306 | 220016506 | 1.58 | 40.8 | Disease modification (D) | 2015-02-23 | 2015-02-23 | Cisplatin | N | N | 220036358 | DABRAFENIB + TRAMETINIB |
| 220009307 | 220016506 | 1.82 | 0 | Curative (C) | 2015-06-28 | 2015-07-01 | Docetaxel | N | Y | 220036358 | IDARUBICIN |
| 220009308 | 220016506 | 1.8 | 0 | Curative (C) | 2014-04-30 | 2014-05-17 | ALEMTUZUMAB + BUSULFAN + FLUDARABINE | N | N | 220036358 | ATG + BUSULFAN + FLUDARABINE |
| 220009309 | 220016506 | 1.53 | 0 | Curative (C) | 2017-04-17 | 2017-04-24 | BOSUTINIB | 02 | N | 220036358 | CISPLATIN + ETOPOSIDE + RT |
| 220009310 | 220016506 | 1.85 | 86 | Curative (C) | null | 2014-05-20 | Cisplatin +Fluorouracil (3 wk) | N | N | 220036358 | PONATINIB |
| 220009311 | 220022171 | 1.73 | 61.6 | Disease modification (D) | 2015-02-01 | 2015-02-01 | BEP 3 day | 02 | N | 220036377 | CYCLOPHOSPHAMIDE + LENALIDOMIDE |
| 220009312 | 220022171 | 1.64 | null | Curative (C) | 2013-12-07 | 2013-12-28 | Bendamustine + prednisolone | 2 | N | 220036377 | CYTARABINE INTRATHECAL |
| 220009313 | 220003777 | 1.72 | 123 | Palliative (P) | 2017-10-07 | 2017-10-07 | Vemurafenib | N | N | 220036380 | BEVACIZUMAB + PACLITAXEL |
| 220009314 | 220003778 | 0 | 55.6 | Disease modification (D) | 2015-12-02 | 2015-12-03 | Cisplatin + Etoposide (3 day) | 02 | N | 220036383 | DABRAFENIB + TRAMETINIB |
| 220009315 | 220003779 | 1.57 | 77 | Palliative (P) | 2015-09-19 | 2015-09-22 | Melphalan oral | 02 | N | 220036384 | CETUXIMAB + CISPLATIN + FLUOROURACIL |
| 220009316 | 220012040 | 1.67 | 101.1 | Curative (C) | 2018-02-12 | 2018-02-19 | Cisplatin | 2 | N | 220036385 | CYTARABINE + MITOXANTRONE |
| 220009317 | 220003780 | 1.6 | 0 | Disease modification (D) | 2014-01-31 | 2014-01-31 | LANREOTIDE | 02 | N | 220036386 | CYCLOPHOSPHAMIDE HIGH DOSE |
| 220009318 | 220003781 | 1.8 | null | Palliative (P) | 2014-01-28 | 2015-09-08 | GEMTUZUMAB OZOGAMICIN | N | N | 220036387 | LENALIDOMIDE |
| 220009319 | 220003781 | null | null | Disease modification (D) | 2016-11-28 | 2016-11-28 | Fludarabine + Melphalan RIC Allo | N | N | 220036387 | CYTARABINE INTRATHECAL |
| 220009320 | 220003782 | 1.83 | null | null | null | 2015-03-01 | Pemetrexed | null | null | 220036392 | LENALIDOMIDE |
| 220009323 | 220003785 | null | 84.9 | Curative (C) | null | 2013-09-18 | SPIRIT 2 TRIAL | N | N | 220036395 | ATG + BUSULFAN + FLUDARABINE |
| 220009324 | 220003786 | 1.66 | 77.7 | Curative (C) | 2017-01-22 | 2017-01-22 | Cisplatin + Pemetrexed | 2 | N | 220036397 | CHOP R |
| 220009325 | 220003787 | 1.67 | null | null | 2017-10-04 | 2017-10-18 | EC | null | null | 220036404 | CAPECITABINE |
| 220009326 | 220003788 | 0 | 67 | Curative (C) | 2016-03-02 | 2016-03-16 | CISPLATIN + FLUOROURACIL | N | Y | 220036408 | TRIPLE INTRATHECAL |
| 220009327 | 220003789 | null | null | null | 2013-02-07 | 2013-02-22 | FLUDARABINE | N | N | 220036409 | ABIRATERONE |
| 220009328 | 220003790 | 1.82 | 70.3 | Palliative (P) | 2014-05-30 | 2014-06-19 | CHOP R - 21 days | N | Y | 220036411 | SORAFENIB |
| 220009329 | 220003791 | 1.65 | 85 | Disease modification (D) | 2017-03-26 | 2017-03-26 | CHOP R - 21 days | N | Y | 220036412 | CYCLOPHOSPHAMIDE + LENALIDOMIDE |
| 220009330 | 220003791 | 1.69 | 84.4 | Curative (C) | 2016-10-29 | 2016-10-29 | Vemurafenib | N | N | 220036412 | FBC |
| 220009331 | 220003792 | null | null | Curative (C) | 2015-02-28 | 2015-02-28 | Triple / Double Intrathecal Therapy | N | N | 220036414 | CARBOPLATIN + RT |
| 220009336 | 220003794 | 1.86 | null | null | 2014-12-25 | 2014-12-26 | Cabazitaxel | N | N | 220036423 | CHLORAMBUCIL + OBINUTUZUMAB |
| 220009337 | 220003795 | 1.52 | null | null | 2017-12-01 | 2017-12-06 | Arsenic trioxide | N | N | 220036425 | FLUOROURACIL |
| 220009338 | 220003796 | 1.7 | 76 | Not known (9) | 2013-03-22 | 2013-03-25 | CYTARABINE + FLUDARABINE | N | N | 220036427 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 220009339 | 220003796 | 1.69 | 63.9 | Curative (C) | 2016-04-16 | 2016-04-16 | BOSUTINIB | N | N | 220036427 | FLUDARABINE + MELPHALAN |
| 220009343 | 220003797 | 1.67 | null | Curative (C) | 2015-05-22 | 2015-06-09 | UKALL14- Ph 1 Induction | N | null | 220036435 | CHOP R |